title: [Pityriasis rubra pilaris after vaccination].
abstract: BACKGROUND
  Pityriasis rubra pilaris (PRP) following vaccination is rarely described in the literature. We report a case of PRP occurring two weeks after measles-mumps-rubella (MMR) vaccination.
  
  
  METHODS
  A 17-month-old infant was referred for a rash appearing two weeks previously. The child was presenting diffuse erythematous scaly exanthema with follicular papules and orange palmoplantar keratoderma. The clinical features were highly evocative of PRP. The histology was non-specific, displaying epidermal acanthosis with a regular and thick parakeratosis, and without any impairment of the follicular infundibulum. An MMR vaccination had been given two weeks before onset of the rash. Treatment with topical corticosteroids and emollients proved effective.
  
  
  CONCLUSIONS
  Post-vaccinal PRP is rarely described in the literature. We report only the 3rd case. The first case concerned a 32-year-old woman presenting two episodes of PRP 10 days after diphtheria-tetanus-polio vaccination. The second case concerned a 47-year-old woman presenting PRP 18 days after anti-influenza vaccination and requiring treatment with acitretin. No cases have been described with MMR. These three vaccines (DTP, Tetragrip and ROR) have no shared pharmacological constituents, and the trigger mechanism could be immunological or parainfectious.
  
  
  CONCLUSIONS
  Questioning about recent vaccination during history taking appears necessary to assess the importance of this trigger factor as well as the mechanism responsible for the onset of PRP.
authors.affiliation: Service de dermatologie, hôpitaux de Brabois, bâtiment Philippe-Canton, 4, rue du Morvan, 54500, Vandoeuvre-les-Nancy, France. nbbouchra1979@hotmail.com
authors.forename: B
authors.initials: B
authors.lastname: Naciri Bennani
authors.forename: H
authors.initials: H
authors.lastname: Cheikh Rouhou
authors.forename: J
authors.initials: J
authors.lastname: Waton
authors.forename: J-F
authors.initials: JF
authors.lastname: Cuny
authors.forename: G
authors.initials: G
authors.lastname: Bassegoda
authors.forename: P
authors.initials: P
authors.lastname: Trechot
authors.forename: A
authors.initials: A
authors.lastname: Barbaud
authors.forename: J-L
authors.initials: JL
authors.lastname: Schmutz
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D004643:Emollients / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D022542:Measles-Mumps-Rubella Vaccine / Q000009:adverse effects*; D010916:Pityriasis Rubra Pilaris / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D014611:Vaccination
chemical_list: D000305:Adrenal Cortex Hormones; D004643:Emollients; D022542:Measles-Mumps-Rubella Vaccine